Latest Commercialization News

OncoSil Medical’s CEO Nigel Lange has agreed to a 10% salary reduction, opting instead to receive shares at a significant premium, reinforcing executive commitment to shareholder value and cost discipline.

The US Department of Commerce has finalized hefty antidumping and countervailing duties on Chinese graphite active anode materials, a move expected to strengthen Syrah Resources’ competitive edge in North America and accelerate its US operations.

Axel REE is fast-tracking field recovery trials at its Caladão Project, leveraging proven in situ recovery methods and a rare gallium resource to position itself uniquely in the critical minerals space.

Robex Resources has officially reached commercial production at its Kiniero Gold Project in Guinea, marked by a significant first shipment of over 6,300 ounces of gold. This milestone sets the stage for the company’s strategic growth and upcoming merger plans.

Entropy Neurodynamics has been granted an Australian patent for its novel two-phase IV infusion method administering psilocybin and psilocin, securing exclusive rights through 2042 and strengthening its lead asset TRP-8803’s competitive position.

Charter Hall Long WALE REIT has reported steady earnings growth and a significant portfolio valuation uplift in its half-year results, reaffirming its FY26 guidance despite trading at a notable discount to net tangible assets.

Tamboran Resources Corporation reported a 26% reduction in half-year losses as it progresses key natural gas projects in Australia’s Beetaloo Basin and prepares for a major acquisition of Falcon Oil & Gas Ltd.

Tamboran Resources has marked significant milestones in the Beetaloo Basin with successful drilling, major capital raises, and a new CEO appointment, targeting first gas sales in Q3 2026.

Temple & Webster Group Limited reported a robust 20% revenue increase to $376 million in the first half of FY26, maintaining momentum towards its $1 billion revenue target by FY28. The company’s strategic investments in AI, exclusive products, and new markets like New Zealand underpin its expanding market presence.

Temple & Webster has reported a robust 20% increase in half-year revenue to $376 million, expanding its market share and launching successfully into New Zealand. EBITDA remains within guidance despite new market investments.

Temple & Webster reported a 20% revenue increase to $375.9 million for H1 FY26, driven by record active customers and exclusive product growth. However, profit before tax fell 25% to $9.4 million, impacted by investments in New Zealand and higher marketing spend.

Oneview Healthcare reported a robust 21% increase in revenue for FY2025, driven by recurring revenue growth and new customer acquisitions. The company is advancing AI-powered solutions and targeting operational breakeven in 2026.